Abstract
Background:Adaptive immunity is crucial in cardiovascular and renal inflammation/fibrosis upon hyperactivation of mineralocorticoid receptor. We have previously demonstrated that dendritic cells can respond to mineralocorticoid receptor activation, and the neutrophil gelatinase-associated lipocalin (NGAL) in dendritic cells is highly increased during aldosterone (Aldo)/mineralocorticoid receptor-dependent cardiovascular damage. However, the interrelationship among dendritic cells, target organs inflammation/fibrosis induced by mineralocorticoid receptor, and NGAL-dependence remains unknown.Objective:We studied the role of dendritic cells in mineralocorticoid receptor-dependent tissue remodeling and whether NGAL can modulate the inflammatory response of dendritic cells after mineralocorticoid receptor activation.Methods:Cardiovascular and renal remodeling induced by Aldo and high-salt diet [nephrectomy-Aldo-salt (NAS) model] were analyzed in CD11c.DOG mice, a model which allows dendritic cells ablation by using diphtheria toxin. In addition, in-vitro studies in NGAL-knock out dendritic cells were performed to determine the immunomodulatory role of NGAL upon Aldo treatment.Results:The ablation of dendritic cells prevented the development of cardiac hypertrophy, perivascular fibrosis, and the overexpression of NGAL, brain natriuretic peptide, and two profibrotic factors induced by NAS: collagen 1A1 and connective tissue growth factor. We determined that dendritic cells were not required to prevent renal hypertrophy/fibrosis induced by NAS. Between different immune cells analyzed, we observed that NGAL abundance was higher in antigen-presenting cells, while in-vitro studies showed that mineralocorticoid receptor stimulation in dendritic cells favored NGAL and IL-23 expression (p19 and p40 subunits), which are involved in the development of fibrosis and the Th17-driven response, respectively.Conclusion:NGAL produced by dendritic cells may play a pivotal role in the activation of adaptive immunity that leads to cardiovascular fibrosis during mineralocorticoids excess.
Original language | English |
---|---|
Pages (from-to) | 1482-1492 |
Number of pages | 11 |
Journal | Journal of Hypertension |
Volume | 37 |
Issue number | 7 |
DOIs | |
State | Published - 2019 |
Bibliographical note
Funding Information:The work was supported by FONDECYT Iniciación 11150542 (C.A.A.), CONICYT-Doctorado 21130482 (P.A.), FONDECYT-Postdoctorado 3160383 (C.P.), FONDECYT-Regular grants 1130550 and 1171869 (L.M.), 1170093 (R.P.), CONICYT-Basal AFB 170004 (R.P.), The Millennium Institute on Immunology and Immunotherapy (MIII; P09/ 016-F ICM), Fondation de France (2014-00047968), ANR MRFOCUS (ANR-15-CE14-0032-02), and the Fight-HF Avenir investment program (ANR-15-RHUS-0004) (F.J.).
Publisher Copyright:
© 2019 Wolters Kluwer Health, Inc. All rights reserved.
ASJC Scopus subject areas
- Internal Medicine
- Physiology
- Cardiology and Cardiovascular Medicine